New Zealand's BioOra Limited and Canada's Octane Biotech have announced a significant collaboration to advance cancer treatment. The companies signed a Letter of Intent to co-develop and deploy CAR-T therapies using Octane's automated Cocoon® platform. This strategic partnership aims to scale manufacturing and dramatically increase patient access to these life-saving cell therapies across the globe.
Strengthening an Established Partnership
This new agreement expands upon a successful existing relationship between the two biotechnology firms. BioOra already utilizes Octane's Cocoon Platform to produce its Atla-Cel therapy for a clinical trial in New Zealand. The ongoing ENABLE-2 trial is evaluating this CD19-targeted CAR-T therapy for patients with relapsed or refractory B-cell lymphoma.
Advanced Automation for Scalable Manufacturing
A key element of the expansion is BioOra's new manufacturing facility currently under construction in Christchurch. The BioOra Health & Technology Centre is specifically designed to operate multiple Cocoon systems concurrently. This infrastructure will enable the company to meet the growing regional demand for CAR-T and other advanced cell therapies efficiently.
The collaboration leverages the Cocoon Platform's automated design to enhance operational efficiency and increase production throughput. This is expected to significantly reduce the vein-to-vein time, which is the total duration from cell collection to infusion. Ultimately, this creates a more responsive and effective model for delivering highly personalized cancer treatments to patients in need.
Leadership from both companies expressed optimism about the partnership's potential to redefine therapy access. BioOra CEO John Robson highlighted the plan to scale their proven New Zealand model for expansion into Australia. Timothy Smith, CEO of Octane, noted that the collaboration sets a new standard for deploying automated cell therapy production globally.
Expanding Global Reach and Innovation
The primary strategic goal is to extend the availability of these advanced treatments beyond New Zealand. The initial focus will be on Australia, with plans for further expansion into additional international markets. This move aims to establish a major cell therapy manufacturing hub in the Southern Hemisphere to serve a broader patient population.
The partnership also intends to develop fully integrated, end-to-end manufacturing solutions for BioOra's products. This involves creating a closed system from cell collection and automated processing to the final product release. Such innovations are designed to simplify complex workflows, making CAR-T therapy more practical and accessible for healthcare systems worldwide.
According to BioOra board member Dr. Laurence Cooper, a pioneer in the field, manufacturing complexity has long limited CAR-T access. He stated that aligning automation with advanced therapeutics is crucial for expanding availability to more patients. This vision supports BioOra's ambition to become the first commercial CAR-T company in the Southern Hemisphere.
The collaboration between BioOra and Octane Biotech marks a pivotal step toward democratizing access to advanced cell therapies. By combining BioOra's clinical pipeline with Octane's automated manufacturing technology, the partnership is poised to overcome critical production bottlenecks. This strategic alliance holds the promise of delivering transformative cancer treatments more efficiently to patients in the Asia-Pacific region and beyond.